Maddi Hebebrand, MC, Associate Editor

PN is increasingly recognized as a common and severe inflammatory skin disease disproportionately affecting patients with darker skin tones.

Click through this slideshow to see what faces familiar to Dermatology Times will be on the speaker stand at Fall Clinical this week.

Peter Lio, MD, describes Fall Clinical as an energizing, high-level dermatology meeting focused on practical takeaways and collaboration.

Biologics, JAK inhibitors, and evolving treatment paradigms headline the Fall Clinical 2025 agenda.

Fall Clinical 2025 continues its tradition of blending cutting-edge science with practical insights for the modern dermatologist.

New evidence supports biologic agents as precise, better-tolerated alternatives to systemic immunosuppressants for life-threatening dermatologic emergencies.

The findings reinforce dupilumab as a safe, long-term cornerstone therapy for pediatric AD, with emerging flexibility in treatment scheduling.

The resubmission includes additional data and analyses addressing prior FDA concerns and is now classified as a complete response under a Class II review.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

In the ARCADIA LTE, nemolizumab maintained significant and progressive improvements in skin and itch outcomes for up to 104 weeks.

The CHMP opinion follows recent US FDA approval, positioning Libtayo as the first immunotherapy approved for adjuvant treatment in high-risk CSCC.

The episode underscores the clinical value of listening to patient advocates who bring firsthand understanding of disease impact.

Through 3 complex cases, participants explored practical ways to integrate agents like clascoterone and tazarotene into daily practice.

The trial evaluates ritlecitinib's efficacy for severe alopecia areata, utilizing innovative external placebo controls for enhanced patient outcomes.

Researchers found that while 96% of respondents use social media daily, most dermatologic information encountered online remains inaccurate or non-evidence-based.

Mark Kaufmann, MD, discusses how patient realities shape psoriasis treatment choices.

A recent case reinforced excimer laser therapy as a precise, efficient, and well-tolerated approach in managing cutaneous T-cell lymphoma variants.

If passed, the Safe Step Act could reduce treatment delays by prohibiting step therapy for FDA-labeled, guideline-supported agents.

Researchers found new patients incurred 40% higher consultation costs due to longer clinician interaction times.

Palvella surpassed enrollment goals in its Phase 3 SELVA trial, enrolling 51 patients at leading US vascular anomaly centers.

Explore the top headlines of the week, including insights on the latest clinical trials, therapeutic updates, and more.

This week, we feature top articles from our sister publications on regulatory updates, clinical trial insights, and more.

Discover how mesotherapy with hyaluronic and succinic acids significantly improves rosacea symptoms, offering a cost-effective adjunct therapy option.

Brownstone’s PDPA session explores how class labeling and insufficient data can mislead clinicians and alarm patients unnecessarily.

A late-breaking EADV presentation revealed that ritlecitinib significantly improved outcomes in patients with multiple forms of scarring alopecia.

The FDA has approved roflumilast 0.05% cream for atopic dermatitis in children aged 2 years and older, extending its use to a critical pediatric population.

Findings suggest that physical activity alone may not meet the psychosocial needs of vitiligo patients, emphasizing the need for targeted mental health care.

The biologic’s less frequent injections could ease logistical and emotional strain for patients with atopic dermatitis and their families.

Discover the latest IPC consensus on psoriasis severity reclassification, enhancing treatment strategies for better patient outcomes and quality of life.